8-K Announcements
6Material company update
May 7, 2026·SEC
Material company update
Feb 26, 2026·SEC
Material company update
Jan 13, 2026·SEC
Cytek Biosciences, Inc.(CTKB)Earnings, Financials & Key Ratios
CTKB•NASDAQ
$4.62
Price updated Jul 6, 2026
AboutCytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitates scientific advances in biomedical research and clinical applications. It offers aurora and northern lights systems, which are spectrum flow cytometers that delivers cell analysis by utilizing the fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells; and aurora cell sorter system, which leverages full spectrum profiling technology to further broaden potential applications across cell analysis. The company also provides reagents and kits, including cFluor reagents, which are fluorochrome conjugated antibodies used to identify cells of interest for analysis on its instruments, as well as 25-color immunoprofiling assay that provides turnkey solutions for identifying major human immune subpopulations for TBNK cells, monocytes, dendritic cells, and basophils. In addition, it offers automated micro-sampling system and automated sample loader system, which are automated plate loaders to integrate seamlessly into the aurora and northern lights systems; SpectroFlo software that provides intuitive workflow from quality control to data analysis for aurora and northern lights systems; and customer support tools. The company serves pharmaceutical and biopharma companies, academic research centers, and clinical research organizations. It distributes its products through direct sales force and support organizations in North America, Europe, China, and the Asia-Pacific region; and through distributors or sales agents in European, Latin American, the Middle Eastern, and the Asia-Pacific countries. The company was formerly known as Cytoville, Inc. and changed its name to Cytek Biosciences, Inc. in August 2015. Cytek Biosciences, Inc. was founded in 1992 and is headquartered in Fremont, California.Show more
- Revenue$201M+0.5%
- EBITDA-$28M-183.2%
- Net Income-$67M-1005.3%
- EPS (Diluted)-0.52-1028.0%
- Gross Margin51.84%-6.5%
- EBITDA Margin-14.1%-181.7%
- Operating Margin-20.04%-95.8%
- Net Margin-33.02%-999.6%
- ROE-18.05%-1082.2%
CTKB Price & Volume
Cytek Biosciences, Inc. (CTKB) stock price & volume — 10-year historical chart
Loading chart...
Stagnant Revenue Growth Challenges Operational Profitability Outlook
Investment Thesis • Updated 2026Q1
VerdictNegative
Growth:Decelerating
Profitability:Negative
Financial:Healthy
Cash Flow:Burning
Primary Risk:Negative operating leverage
Key Thesis Takeaways
- Cytek Biosciences faces a challenging transition as revenue growth decelerated to 6.5% in 2026Q1, signaling potential market saturation in its core flow cytometry segment.
- The company continues to struggle with negative operating leverage, evidenced by a -41.8% operating margin, while persistent net losses and a shrinking cash balance of $65.7M raise concerns regarding long-term capital sustainability.
- Investors should monitor whether management can reverse the trend of negative free cash flow margins, which reached -11.1% in the most recent quarter, before the company's liquidity buffer is further eroded.
Verdict Logic
the company's inability to achieve consistent profitability, highlighted by a -42.7% net margin in 2026Q1, suggests significant execution risk in the current growth environment.
CTKB Growth Metrics
Cytek Biosciences, Inc. (CTKB) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years16.76%
3 Years7.1%
TTM3.61%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-557.69%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-543.14%
Return on Capital
10 Years-5.99%
5 Years-3.64%
3 Years-6.92%
Last Year-9.9%
CTKB Recent Earnings
Cytek Biosciences, Inc. (CTKB) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 7/12 qtrs (58%)●Beat Revenue 4/12 qtrs (33%)
Q2 2026Latest
May 7, 2026Metric
Actual
Est
EPS
$0.12-50.0%
$0.08
Rev
$44M-0.2%
$44M
Q1 2026
Feb 26, 2026Metric
Actual
Est
EPS
$0.01+50.0%
$0.02
Rev
$62M+8.7%
$57M
Q4 2025
Nov 5, 2025Metric
Actual
Est
EPS
$0.01-200.0%
$0.01
Rev
$52M-11.1%
$59M
Q3 2025
Aug 6, 2025Metric
Actual
Est
EPS
$0.01+150.0%
$0.02
Rev
$46M-1.6%
$46M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 7, 2026 | $0.12vs $0.08-50.0% | $44Mvs $44M-0.2% |
| Q1 2026 | Feb 26, 2026 | $0.01vs $0.02+50.0% | $62Mvs $57M+8.7% |
| Q4 2025 | Nov 5, 2025 | $0.01vs $0.01-200.0% | $52Mvs $59M-11.1% |
| Q3 2025 | Aug 6, 2025 | $0.01vs $0.02+150.0% | $46Mvs $46M-1.6% |
Based on last 12 quarters of dataView full earnings history →
Peers Comparison
Key metrics vs top competitors for Cytek Biosciences, Inc. (CTKB)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $4.62 | $596.64M | -8.88 | 0.52% | -33.02% | -18.05% | — | |
| $194.33 | $29.52B | 35.66 | -0.78% | 19.43% | 32.84% | — | |
| $76.01 | $16.97B | 30.53 | 1.74% | 13.18% | 11.01% | — | |
| $25.67 | $1.18B | -21.04 | 3.55% | -29.86% | -10.69% | — | |
| $283.80 | $40.64B | -186.71 | 35.9% | -9.05% | -15.13% | — | |
| $295.15 | $7.97B | 10.59 | 0.65% | 6.52% | 2.4% | — |
Compare CTKB vs Peers
Cytek Biosciences, Inc. (CTKB) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
CTKB SEC Filings & Documents
Cytek Biosciences, Inc. (CTKB) SEC filings — annual & quarterly reports (10-K, 10-Q)
Get notified when CTKB posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
CTKB Frequently Asked Questions
Cytek Biosciences, Inc. (CTKB) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
What is Cytek Biosciences, Inc.'s revenue?
Cytek Biosciences, Inc. (CTKB) reported $204.2M in revenue for fiscal year 2025. This represents a 253% increase from $57.9M in 2019.
How fast is Cytek Biosciences, Inc. growing?
Cytek Biosciences, Inc. (CTKB) grew revenue by 0.5% over the past year. Growth has been modest.
Is CTKB profitable?
Cytek Biosciences, Inc. (CTKB) reported a net loss of $74.0M for fiscal year 2025.
Dividend & Returns
What is CTKB's return on equity?
Cytek Biosciences, Inc. (CTKB) has a return on equity (ROE) of -18.0%. Negative ROE indicates the company is unprofitable.
What is Cytek Biosciences, Inc.'s free cash flow?
Cytek Biosciences, Inc. (CTKB) had negative free cash flow of $12.7M in fiscal year 2025, likely due to heavy capital investments.